TECH OFFERS

AI has the potential to significantly enhance diagnostic efficiency, allowing healthcare providers to quickly analyze medical images (e.g., X-Ray, MRI, CT, PET) and generate preliminary diagnostics for further review. This is achieved through a comprehensive workflow that involves: 1. Leveraging the deep expertise of medical professionals to accurately annotate medical images, creating a robust training dataset for the AI model. 2. Training computer vision models based on these datasets to achieve target performance levels. 3. Continuously refining these models over time through the incorporation of new data. Traditionally, this process demands a team of engineers to set up and maintain multiple tools, making it resource-intensive and costly. The technology offered here is a no-code, end-to-end platform that revolutionizes this process by enabling healthcare professionals to directly contribute their expertise through an AI-assisted image labeling tool. This tool allows technical teams to collaboratively and efficiently label large datasets with pixel-level accuracy. Model training and fine-tuning can then be managed by a single individual, significantly reducing the time from concept to deployment - from months to weeks - while also cutting costs associated with hiring specialized machine learning engineers. The technology owner has worked with universities, hospitals, and MedTech start-ups to develop unique computer vision solutions in the healthcare space. The technology owner is seeking collaborations with healthcare organizations aiming to harness computer vision to enhance operational efficiency and quality of care. Alongside the platform, professional services are available to support development, customize necessary integrations, and ensure the success of client projects. This platform includes the following key features: Labeling Tools for Medical Scans - Supports 2D and 3D scans (e.g., NifTi, DICOM, MPR) - AI-assisted labeling for masks, keypoints, or volume - Collaborative working environment enabling labeling tasks to be distributed, with gates for management review and tie-breaking scenarios for data that are harder to assess - Importable / exportable major annotation formats, including COCO JSON, LabelMe, PascalVOC, COCO MASK, and CSV Width-Height AI-Assisted Labeling  Medical datasets are often large and complex. The AI-assisted labeling feature uses advanced contour analysis methods and deep learning to enable precise labeling with minimal user input. Users simply need to identify areas of interest / not of interest, and the platform will automatically generate accurate masks around the targeted regions. General Specifications - HIPPA and SOC II compliant, with ability to deploy on-premise to protect data security - "One-Click Train" for immediate model training leveraging 50+ foundational models - Audit trails to facilitate approvals for medical AI - documenting characteristics like data sets, model parameters, and model performance This platform addresses one of the major challenges faced by researchers, machine learning engineers, and data scientists in healthcare: the tedious and time-consuming task of data labeling. With this automated segmentation algorithms, teams have successfully labeled thousands of medical images in a fraction of the time typically required. Computational Pathology and Medical Imaging Applications: - Disease Detection and Identification (e.g., Tumor Lesions, Fractures, Foreign Objects) from X-Ray, MRI, and other medical imaging technologies - Anomaly Detection in Blood Cell Scans and Pathology Scans This platform enables healthcare teams to label data significantly faster, utilizing an AI-enabled segmentation tool that requires only a few clicks to create pixel-perfect masks. The tool can be used collaboratively, to divide up the workload between medical professionals, with built-in gates for management review. Given the high level of expertise required for medical data labeling, this platform allows professionals such as doctors and researchers to perform this task up to ten times faster. Additional benefits include a minimal learning curve, as the platform does not require mastery of many different tools. Moreover, it supports an end-to-end workflow, allowing teams to quickly transition from labeled images to trained deep-learning models (e.g., FasterRCNN, MaskRCNN, DeepLabV3, YOLO). The platform also supports the generation of labeled files compatible with multiple popular frameworks, streamlining the process of building and deploying powerful AI models in healthcare. Most importantly, all project IP is owned by the client. This allows MedTech companies to protect their core business. For healthcare systems looking to do in-house development, this fundamentally changes the current economics of AI in healthcare. Instead of pay per use, where costs scale with increased usage, the costs are concentrated into development and use of the AI can scale while costs remain relatively flat. AI-Assisted Image Labeling, Medical Images, Computational Pathology, Computer Vision Infocomm, Video/Image Analysis & Computer Vision, Big Data, Data Analytics, Data Mining & Data Visualisation, Healthcare, Telehealth, Medical Software & Imaging, Healthcare ICT

This technology is a neurointerventional procedure, focusing on transradial access for acute ischemic and hemorrhagic stroke treatment. Traditionally, neurointerventions utilize transfemoral access, but this solution leverages the radial artery for access, providing a safer and more comfortable alternative. By reducing complications and shortening recovery times, the transradial approach significantly enhances patient experience.  The transradial access system comprises three components: a radial access sheath, a selective catheter, and a guiding catheter. Each component is designed to work in harmony, ensuring the system’s compatibility and optimal performance. The radial sheath maintains high structural integrity while reducing radial artery spasm and occlusion. The selective catheter offers multiple proprietary tip shapes for improved access to neuro arteries. The guiding catheter combines distal flexibility and proximal stiffness to ensure smooth catheter pushability and trackability, providing surgeons with an efficient and seamless experience. The trans-radial access catheters for neurosurgery are developed for Asian population whom have narrow arteries.  The technology owner is interested in joint R&D projects to co-develop the technology. The neuro transradial access system comprises three core technologies: the radial access sheath, the selective catheter, and the guiding catheter. Radial Access Sheath: Designed with an optimal balance of flexibility and strength to enable precise navigation through the radial artery. Features a low-profile, thin-walled design to minimize radial artery spasm and ensure patient comfort. Coated with a hydrophilic layer to reduce friction, facilitating smoother sheath insertion and advancement. Selective Catheter: Equipped with a proprietary tip shape that enhances access to critical arteries, including the right/left ICA, ECA, and VA. Incorporates a U-shape stiffness for superior anchorage, preventing slippage during procedures and ensuring stability post-subclavian artery access. Guiding Catheter: Optimal balance of distal flexibility and proximal stiffness. Features a multi-layer design: a polymeric outer layer for flexibility, metallic coils and braids in the mid-layer for added structural support, and a high-wear resistance inner layer to ensure smooth catheter movement within the vasculature. Enables superior pushability and trackability during neurointerventions. This technology is designed for use in neurointervention procedures, with potential applications in the following areas: Aspiration Catheter Microcatheter Intermediate Catheter Distal Delivery Catheter This technology offers several advantages over conventional solutions in the neurointerventional space: Shorter Recovery Time: The design of this system reduces procedural complications and promotes faster recovery times, allowing patients to return to their normal activities sooner. Tailored for the Asian Population: The Trans-Radial Access Catheters are specifically designed for the Asian population, accommodating narrower arteries and ensuring safer and more effective neurointerventional access. Complete Neuro Transradial System: A fully integrated system that provides seamless access from the radial artery to the neurovasculature, minimizing procedural complications. Optimized Radial Sheath: Engineered to reduce radial artery spasm and occlusion, improving patient outcomes and comfort. Selective Catheter with Anchoring Mechanism: The catheter’s design prevents slippage during procedures, enhancing stability and precision during treatments. Guiding Catheter Designed for Optimal Pushability and Trackability: this catheter ensures smooth navigation through the vasculature, improving the overall user experience for surgeons. Medical Device, Neurointerventional, Catheters, Transradial Access, Radial Access Sheath, Selective Catheter, Radial Guide Catheter Healthcare, Medical Devices

In the wake of the COVID-19 pandemic, people have developed new expectations for indoor air quality. It is no longer just about ventilation and purification, but also about providing clean and safe air for a healthier environment. Traditional UVC technology (254 nm) has been widely used in HVAC systems and air purifiers to disinfect airborne pathogens. To ensure its effectiveness, sufficient contact time is required, hence it is often used in unoccupied spaces due to safety concerns.  This solution utilises human-safe 222 nm far-UVC technology which has been shown to be able to effectively inactivate airborne pathogens while maintaining safety since it does not penetrate the outer layer of human skin or eyes. This allows for continuous disinfection of air in occupied spaces. By integrating 222 nm far-UVC technology into HVAC system, including air purification, air monitoring and IoT management platforms, the company offers a complete solution for clean and safe air. With integrated capabilities in both R&D and manufacturing, the company can provide tailor-made solutions for different industry applications. They are seeking collaborations with real estate developers, chain restaurant operators and pathogenic air sampling technology experts to further develop and commercialise this solution. Human-safe 222 nm Far-UVC: An effective and direct disinfection technology, 24x7, no downtime   Green Technology: No chemicals, no mercury, and ozone free Air Quality Monitoring: Multiple sensors IAQ control system New Fresh Air System: Does not rely on fresh air ventilation   Smart IoT System: Enable optimisation of air purification effectiveness and energy efficiency  Reduce Carbon Emission:  Green technology, energy saving This solution could be deployed across various industries, including, but not limited to: Commercial/Residential Complexes Hospitals Hotels and Hospitality Educational Institutions F&B and Catering Operators Indoor Recreational Facilities In addition to indoor occupied spaces, the solution is also applicable in sectors such as the food industry, cold chain, and logistics centres, where secondary pollutants are the major sources of contamination. With the ability to achieve higher number of equivalent air changes, the utilisation of far-UVC for air disinfection offers a more cost effective and energy saving solution for indoor air quality control as compared to traditional air purification methods and reliance on ventilation.  222nm, far-uvc, iaq, covid, flu Green Building, Heating, Ventilation & Air-conditioning, Indoor Environment Quality, Sustainability, Sustainable Living

Immune cell activation and expansion for cell therapy is a strictly regulated process. It demands costly and labour-intensive optimization of cell culture conditions. Major limitations of these processes are cell quality and results consistency. Large amounts of expenses were spent on culture conditions, cell characterizations and quality control (QC) with differing culture protocols and recipes in growing CAR-T cells. This technology has established a biomaterial-based artificial cell platform to replace plastic beads, significantly improving cell stimulation performance. The artificial cells uses polysaccharides, lipids, and proteins to mimic live cells, meeting the demand for reproducibility and standardization while being 100% degradable. To address this gap, a modular, all-signals-in-one microbead-based platform has been developed for the next-generation cell therapy R&D and translation. In this delivery platform design, the modular feature allows rapid ‘plug-and-use’ of multiple surface and soluble signals to grow T-cells ex vivo without the need for extensive setup and integration of culture protocols. This platform aims to provide a seamless and straightforward cell culture experience for the industrial and academic research users to discover new types and applications of immune cell therapy. Additionally, the all-signals-in-one synthetic platform mimics the natural antigen presenting cells to activate and expand T-cells on dish, allowing cell manufacturers to ‘mix-and-grow’ immune cells with reduced effort or technical expertise. This aims to improve the cost-effectiveness and scalability of cell therapy manufacturing. The technology provider is seeking collaborations with cell therapy CDMOs/CMOs in licensing and various R&D developments. The artificial cells are a game-changer in cell therapy, offering a sustainable and environmentally friendly alternative to plastic beads. The core of these cells is made of hydrogel, a biodegradable material that mimics the size and texture of live cells. The hydrogel core is treated with special anchors to allow the coating of lipids, recreating the fluid lipid membrane of real cells. The required activation signals are then docked onto this mobile membrane via avidin-biotin interaction, presenting the signals in the most 'natural' way possible. By mimicking cell-cell interactions, the artificial cells provide enhanced quality signals to target cells. The modular design allows for easy customization of surface signals, enabling selective growth of specific cell types. This versatile platform opens doors to discovering and testing new signal pathways and isolating specific cell types. The technology provider now offers a product for T cell activation and expansion, and is developing working prototypes for regulatory T cell and NK cell activation and expansion. The hydrogel-based artificial cells are not only biodegradable but also have the potential for in vivo immunomodulation, paving the way for vaccines for cancers and autoimmune diseases. This technology empowers researchers to grow better cells quicker and discover specific cell subtypes. Cell therapy manufacturers seeking competitive edges in production speed and quality are ideal commercial partners for this innovative and eco-friendly platform. The proprietary microbead-based platform functions as an artificial cell, with its fluidic membrane surface signals presentation and controlled-released soluble signals. The platform application includes but not limited to: Cell therapy manufacturing: Microbeads can be used to support and supplement ex vivo T-cells activation and expansion. Cell-based therapies and regenerative medicine: Microbeads can be engineered to mimic the functions of specific cell types, such as T-cells for immunotherapy, pancreatic cells for diabetes and glial cells for neuron repair. Versatile high-throughput screening platform bridging in-silica signals discovery and in-vitro validation: The ‘plug-and-use’ microbead-based platform feature, together with the versatility avidin-biotin technology and accessibility of commercial biotinylated recombinant proteins and antibodies enable rapid in vitro tests of novel biochemical signals and combinations on cell functions.   Cell therapy is the next pillar of medicine for the treatment of chronic diseases, such as cancer, autoimmune disorders etc.  The cell expansion market was valued at 41.3B USD in 2021 with a CAGR of 12.6%. Nonetheless, many cell therapeutics are still in the discovery and pre-clinical phase. The clinical translation is hampered by suboptimal culture process, unstandardized protocol, limitations of research tools and ex vivo signals delivery platform and high demand of technical expertise. The predominant player in cell expansion and activation market is the magnetic microbeads with emerging alternatives such as antibody tetramers, polymeric nanomatrix, nanosystems with varying shapes/size/stiffness to expand the cell growth tools, facilitate R&D and translational research of cell therapy. This biomaterial-based artificial cell platform revolutionizes cell therapy by providing a sustainable, eco-friendly, and high-performance alternative to current synthetic solutions. Key Advantages: Environmentally Friendly: 100% biodegradable, mitigating the environmental impact of plastic beads. Versatility: Enables the expansion of diverse cell types unserved by current plastic bead-based solutions, such as tumor infiltrating lymphocytes (TILs), natural killer (NK) cells and regulatory T cells. Superior Performance: Up to 2 times faster immune cell expansion compared to state-of-the-art plastic microbeads, with less cell exhaustion. Streamlined Process: Eliminates the need for de-beading, as the hydrogel-based artificial cells degrade at predetermined timepoints. This artificial cell platform empowers researchers and cell therapy manufacturers to: Contribute to a more sustainable and eco-friendly future in cell therapy. Expand diverse immune cells faster and more efficiently. Produce higher quality cells with less exhaustion. Grow challenging cell types, such as NK cells, with the ability to re-stimulate growth. Simplify their processes by eliminating the need for de-beading. Cell and Gene Therapy, Biomaterials, Immune Cell Therapy, Artificial Antigen Presenting Cells, Cell Expansion, Cell Culture, CGT, Advanced Medicinal Products, ATMPs, CAR-T, CAR-NK, Replacing Plastics, Microcarrier Healthcare, Pharmaceuticals & Therapeutics, Life Sciences, Industrial Biotech Methods & Processes, Biotech Research Reagents & Tools

This technology focuses on the production of high-quality graphene oxide (GO) and reduced graphene oxide (rGO), designed for various industrial applications. Graphene oxide demonstrates superior electrical, thermal, and mechanical properties, making it an ideal candidate for industries such as electronics, energy storage, coatings, and composites. By reducing GO to rGO, its conductive properties can be enhanced. With the rising demand for advanced nanomaterials that enhance performance while supporting sustainable manufacturing practices, this technology ensures consistent quality and cost-effectiveness of GO and rGO for commercial use. The technology owner is seeking for joint R&D collaborations with industrial manufacturers and companies focused on sustainable materials innovation. Target partners include those in electronics, energy, and materials science sectors, interested in integrating graphene oxide into their new product development pipeline. The technology focuses on the process and production of graphene oxide in both powder and dispersion forms. Some features of the GO include: Can be reduced to rGO to enhance conductive properties Excellent dispersibility in water, ideal for integration into coatings, composite materials, and energy storage solutions Customisable to meet specific industrial needs i.e., varying particle sizes and surface chemistries This graphene oxide technology is applicable across several sectors, including electronics, energy storage, paints and coatings, water filtration, and composites. It enhances mechanical strength and conductivity, providing industries with innovative solutions for next-generation batteries, conductive inks, and advanced coatings. Industries prioritizing sustainability and high-performance materials can leverage this technology to improve efficiency, durability, and eco-friendliness in their products. This technology offers unparalleled scalability, customization, and quality control, providing industries with a reliable source of high-performance, environmentally friendly materials. By integrating graphene oxide into various applications, companies can significantly improve the durability, conductivity, and sustainability of their products, thus gaining a competitive edge. graphene oxide, reduced graphene oxide, nanomaterials, conductive, energy storage, coatings Materials, Semiconductors, Nano Materials, Manufacturing, Chemical Processes

Fungal-like Adhesive Materials (FLAM) represent an innovative family of materials inspired by the cell walls of fungus-like oomycetes. FLAMs are engineered by organizing the two most abundant and widely available natural molecules in their native configuration, resulting in a material that is lightweight, durable, and highly cost-effective. This groundbreaking composite is fully biodegradable, eliminating the need for organic solvents or synthetic materials, making it an eco-friendly alternative. FLAM can be locally produced as part of natural ecological cycles, contributing to sustainable manufacturing and ensuring long-term resource security for industries. In addition to its sustainability benefits, FLAM’s versatility allows it to be easily molded or processed with traditional manufacturing techniques, opening the door to a wide range of applications across various industries. This technology has been locally produced in Singapore as a by-product of waste management. The technology owner is looking for collaboration in test-bedding. FLAM can replace the use of plastic and wood in many applications.  Good strength-to-weight ratio: Inspired by the cell walls of fungus-like oomycetes by combining cellulose and chitin to give a lightweight and strong material. Biodegradable: Fully biodegradable composite with no synthetic additives. Non-toxic: Adding small amounts of a chitinous molecules enables the use of cellulose without any chemical modification and without the use of harmful solvents.  Easy processing: Compability with wood-working machinery and traditional manufacturing methods. FLAM can replace the use of wood in most applications, such as but not limited to: Furniture Architectural components  General and food packaging  Daily household items Large industrial parts: e.g. windmill blades, impact resistors Eco-friendly: Non-toxic, biodegradable material. Lightweight and strong: Able to replace wood and plastic material in most applications. Cost effective: Comparable to high density polyurethane foam. sustainable material, sustainable, biomaterial, FLAM, eco-friendly, biodegradable Materials, Bio Materials, Sustainability, Low Carbon Economy

The leather industry, long dependent on livestock farming, is facing growing criticism for its significant environmental impact. Leather production contributes to deforestation, high water consumption, and the release of methane—a potent greenhouse gas—from livestock farming. Additionally, the tanning and dyeing processes generate hazardous waste and chemicals, leading to air and water pollution. While synthetic leather offers an animal-free alternative, it relies heavily on petroleum-based plastics like polyurethane (PU) and polyvinyl chloride (PVC), which contribute to microplastic pollution and rely on finite fossil fuel resources. Meanwhile, large quantities of agricultural waste, such as cocoa shells, mangosteen peels, and durian fibers, often end up in landfills, where they release methane as they decompose, further exacerbating environmental concerns. This technology transforms agricultural waste into a sustainable, plant-based leather alternative that addresses both environmental sustainability and the rising demand for animal-free products. By utilizing discarded cocoa shells, along with mangosteen peels and durian fibers, it offers several benefits. The natural fibers from durian provide antibacterial properties, making it ideal for products like shoes, bags, and jackets prone to bacterial buildup. Additionally, the production process emits fewer greenhouse gases, consumes less water, and repurposes agricultural waste, aligning with circular economy principles. This eco-friendly material is biodegradable and designed for recycling, offering a more sustainable alternative to traditional and synthetic leathers. The technology owner is looking for collaborations with textile/furniture companies that focuses on sustainability.  Plant-Based Vegan Leather Synthesis Innovation Raw Materials: Cocoa shells, mangosteen peels, durian fibers, and other fruit peels are used as primary materials. Agricultural waste is ground into fine particles for the production process. Formulation: Materials are mixed with research-specific binding agents to create a plant-based leather precursor. Formulations and ratios are designed to ensure proper texture, elasticity, and durability. Production Process: The mixture is spun and poured into custom-designed moulds. A specialized resin coating is applied to achieve the desired thickness (approximately 0.8 mm). The material is then placed in a drying oven to remove moisture. Post-Processing: The vegan leather is cleaned and inspected for quality, including surface texture, flexibility, and durability. Testing: The material undergoes rigorous testing for surface testing, flexibility, durability and functionality. The production process for plant-based leather emits fewer greenhouse gases and consumes less water and natural resources. Here are the potential applications, but not limited to: Fashion: Handbags, belts, outerwear and clothing Upholstery and Interior Design: Furniture coverings and automotive interiors Footwear: Sustainable anti-bacterial footwear Sports equipment: Vegan leather alternatives for sports gear – gloves or protective wear   Eco-friendly and Sustainable: Made from agricultural by-products (e.g., cocoa husks, mangosteen peels), reducing waste and lowering the carbon footprint compared to animal leather and plastic alternatives. Cruelty-free and Ethical: Derived from plants, offering a humane alternative to animal leather, appealing to the growing demand for cruelty-free products. Reduced Resource Usage: Requires less water, energy, and chemicals than traditional leather production, minimizing harmful pollutants like heavy metals. Biodegradable: More likely to break down naturally over time, reducing long-term waste compared to synthetic leather made from PVC or other plastics. Versatile and High-Quality: Can mimic the look and feel of traditional leather, customizable in texture, colour, and finish, suitable for fashion, accessories, and automotive interiors. Market Differentiation: Meets the growing demand for sustainable, vegan products, helping brands differentiate with eco-conscious, ethical offerings. sustainable materials, vegan leather, plant-bsaed leather, cocoa shell leather, durian fibre leather, eco-friendly fashion, biodegradeable materials, leather alternatives, low environmental impact Sustainability, Circular Economy, Sustainable Living

Superoxide dismutase (SOD) is a key antioxidant enzyme that protects cells from oxidative stress by catalysing the conversion of superoxide radicals into less harmful molecules like oxygen and hydrogen peroxide. These radicals are produced during normal cellular metabolism but can cause significant damage to DNA, proteins, and lipids if not neutralised. SOD helps maintain cellular integrity by reducing this damage, supporting overall health and longevity. Given its role in protecting cell damage, SOD has been utilised in skincare products, cosmeceuticals, dietary supplements, medical and therapeutic products as well as functional foods. Current methods to produce SOD include natural extraction from plants, microbial fermentation and recombinant DNA technology. However, challenges such as low yield, variation in quality and concentration, high costs and regulatory issues still remain. The technology owner uses specific strains of microorganism and advanced biotechnology processes to produce SOD at high yields via fermentation in a sustainable and efficient manner. The enzyme is then extracted and concentrated during downstream processing. This technology could ensure a consistent and scalable supply of SOD for commercial use. The company is seeking collaborations with skincare brands and cosmetic manufacturers interested in co-developing or licensing the technology for mass-market production and distribution. Sustainable and efficient manufacturing: Produced through microbial fermentation using specific and proprietary microorganisms to ensure high yield and purity. High enzyme activity: SOD activity is measured in units (U), typically ranging from 2,000 to 20,000 U/ml, depending on the downstream process, and intended application. pH stable: Active across a wide pH range, typically stable between pH 4.5 to 8.5, making it suitable for various formulations in supplements and cosmetics. Temperature stable: Optimal activity at temperatures between 20°C and 40°C. Some formulations may include stabilisers to maintain activity at higher temperatures. Water soluble: Allowing easy incorporation into aqueous formulations for cosmetics or supplements. Varied formats: Available in liquid concentrate or lyophilised (freeze-dried) powder form, depending on application and customer requirements. Long shelf life: Typically 12-24 months when stored at -20°C for lyophilised forms, with stability maintained through proper storage and packaging. Beyond its biological role, SOD has applications in nutraceuticals and dietary supplements. It could be used to enhance the body's natural defence mechanisms, particularly in combating oxidative stress that contributes to aging and chronic conditions. SOD supplements have potential to reduce inflammation, improve immune function, and support joint health. Some studies suggest that SOD may help mitigate symptoms of conditions like arthritis, asthma, and exercise-induced muscle damage.  In addition to health supplements, SOD is also utilised in the cosmetic industry due to its skin-protective properties. It helps reduce the impact of environmental factors, such as UV radiation and pollution, which accelerate skin aging. There are also potential pharmaceutical applications for reducing oxidative stress. The global market for superoxide dismutase (SOD) is experiencing significant growth, driven by increasing consumer demand for natural antioxidants, health supplements, sports nutrition, and anti-aging solutions. Superoxide dismutase market size was valued at USD 100 Billion in 2023 and is expected to reach USD 145.48 Billion by the end of 2030 with a CAGR of 5.6% (Verified Market Reports, 2024). Consumers are also leaning towards eco-friendly, naturally sourced, and sustainably produced products. SOD, produced via fermentation, aligns with this demand, offering a clean, green alternative to synthetic antioxidants, positioning it favourably in the market. Its unique properties as a potent antioxidant, coupled with advancements in production and delivery methods, position it as a high-value ingredient in the expanding nutraceutical, cosmetic, and pharmaceutical markets. Sustained action: Unlike non-enzymatic antioxidants like vitamin C or E, which are consumed in the process of neutralising free radicals, SOD continues to work through a catalytic cycle. This offers long-lasting protection against oxidative damage at lower dosages. Targeted oxidative stress protection: SOD directly neutralises superoxide radicals, one of the reactive oxygen species (ROS) that contribute to chronic inflammation, aging, and various diseases. Traditional antioxidants are less selective and less effective at targeting this specific radical. Versatile applications: SOD can be used in diverse formulations, from dietary supplements to topical skincare products which broaden its application in health, wellness, and cosmetics industries. Personal Care, Cosmetics & Hair, Nutrition & Health Supplements, Life Sciences, Industrial Biotech Methods & Processes, Sustainability, Sustainable Living

Liver Fluke Infection (Opisthorchis viverrine) caused by the ingestion of raw or uncooked fish containing parasitic worms is a significant health problem in several countries, especially Southeast Asia. This infection while not deadly, can cause acute gastro-hepatic inflammation and long-term infection leading to carcinogenesis of an aggressive bile duct cancer (Cholangiocarcinoma-CCA) if left undiagnosed and untreated. The lifespan of the human liver fluke ranges from 9 to 13.5 years. Hence, early diagnosis of O. viverrini infection is valuable in preventing the infection from worsening and causing complications. Current diagnostic method uses stool examination (restricted by low parasite egg numbers in the specimen), imaging tests of liver and blood tests for antibodies. Cysteine protease is a group of protease enzymes characterized in numerous infectious pathogens. This technology has discovered a single-chain variable fragment (scFv) antibody target against cathepsin F of O. viverrini (OvCatF) by using phage display technologies. Cathepsin F is an enzyme with a half-life that is highly released during the infection, detecting this protein could reflect the current infection. This novel scFv antibody holds great potential in the field of parasitology and infectious diseases, and the characterization of their immunological properties could pave the way for the development of an effective rapid diagnostic kit in the future. The technology owner is seeking for medical device companies to develop this potential target as a practical diagnostic procedure for O. viverrini infection in humans in the future. This invention is a mouse single-chain variable fragment (scFv) antibody that specifically recognizes the epitope on the cathepsin F protein of the human liver fluke Opisthorchis viverrini (OvCatF) on amino acid residues 11 to 30. This scFv antibody contains variable fragments (Fv) of both heavy chain (VH) and light chain (VL), which are connected by a disulfide bond to form a single chain. This scFv antibody is selected by biopanning from the murine naïve single-chain variable fragments (scFv) library and produced by recombinant protein technologies. The ultimate objective of this invention is to develop an effective diagnostic tool for opisthorchiasis and cholangiocarcinoma in the future. Antibody for development and diagnosis of Opisthorchis viverrini infection and cholangiocarcinoma (bile duct cancer). Therapeutic antibody for Opisthorchis viverrini infection. The UVP of this developed scFv antibody is such that it recognizes specific epitopes that have never been used, conserves less than the other parasites, and make low cross-reactivities. The evaluation of specific recognition of the particular epitopes and detection limits by both computational and laboratory performances demonstrated that the selected recombinant scFv antibodies against OvCatF could bind specifically to rOvCatF, and the lowest detection concentration in the study was only 100ng. This target antibody candiate has the potential to be commercialised for early rapid diagnosis of parasitic infectious disease through the development of a rapid test kit.    Single-chain variable fragment (scFv) antibody, Opisthorchis viverrini, Cathepsin F, Liver Fluke Infection Healthcare, Diagnostics, Medical Devices, Pharmaceuticals & Therapeutics